Tiedemann Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Tiedemann Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$295K	Buy	4,045 +8	+0.2%	+$639	0.01%	223
2023 Q2	$336K	Buy	+4,037	New	+$338K	0.01%	199
2022 Q2	–	Sell	-8,742	Closed	-$786K	–	306
2022 Q1	$786K	Buy	8,742 +868	+11%	+$80.2K	0.04%	157
2021 Q4	$882K	Buy	7,874 +231	+3%	+$27.9K	0.04%	154
2021 Q3	$961K	Sell	7,643 -776	-9%	-$99.9K	0.05%	143
2021 Q2	$1.14M	Hold	8,419	–	–	0.05%	161
2021 Q1	$1.14M	Sell	8,419 -4,034	-32%	-$604K	0.05%	150
2020 Q4	$1.75M	Buy	12,453 +45	+0.4%	+$5.76K	0.08%	109
2020 Q3	$1.38M	Buy	12,408 +175	+1%	+$19.6K	0.07%	151
2020 Q2	$1.37M	Sell	12,233 -6,482	-35%	-$638K	0.07%	141
2020 Q1	$1.45M	Buy	18,715 +11	+0.1%	+$974	0.09%	128
2019 Q4	$1.78M	Sell	18,704 -4,887	-21%	-$423K	0.09%	121
2019 Q3	$1.8M	Buy	+23,591	New	+$1.96M	0.09%	129
2019 Q2	–	Sell	-9,615	Closed	-$870K	–	431
2019 Q1	$870K	Hold	9,615	–	–	0.04%	232
2018 Q4	$690K	Buy	+9,615	New	+$775K	0.04%	251

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Tiedemann Advisors's XBI Position: Q3 2023 in Review

Tiedemann Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.2% in Q3 2023, buying an estimated $639 and bringing the position to 4,045 shares worth $295K. The position accounts for 0.01% of the portfolio, ranked #223.

Tiedemann Advisors first reported a position in XBI in Q4 2018 and has held it in 15 quarters since. The position peaked at $1.8M in Q3 2019. 679 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

Tiedemann Advisors held 4,045 shares of State Street SPDR S&P Biotech ETF worth $295K as of Q3 2023.
Tiedemann Advisors bought 8 State Street SPDR S&P Biotech ETF shares in Q3 2023, an estimated $639.
State Street SPDR S&P Biotech ETF made up 0.01% of Tiedemann Advisors's portfolio in Q3 2023, its #223 holding.
Tiedemann Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and has held it in 15 quarters since.
Tiedemann Advisors's State Street SPDR S&P Biotech ETF position peaked at $1.8M in Q3 2019.
679 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on Tiedemann Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.